Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC

Erika Rijavec, Alice Indini, Michele Ghidini, Gianluca Tomasello, Monica Cattaneo, Francesca Barbin, Francesco Grossi

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: In the last decade, immune checkpoint inhibitors have revolutionized the treatment of several malignancies including non-small cell lung cancer (NSCLC). The inhibition of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed death receptor 1 (PD-1) pathways leads to an activation of the immune response against tumor cells. Thanks to a synergistic effect, the combination of the checkpoint inhibitors nivolumab and ipilimumab has the potential to improve outcomes of NSCLC patients. Areas covered: We provide an overview of clinical trials evaluating the combination of nivolumab and ipilimumab in the first-line treatment of advanced NSCLC patients. Expert opinion: The combination of nivolumab and ipilimumab, alone or with a few cycles of chemotherapy, was demonstrated to be a valid option for first-line treatment of metastatic NSCLC patients without EGFR mutation and ALK rearrangement. However, a better understanding of patients who can benefit from this approach is required.

Original languageEnglish
JournalExpert Review of Anticancer Therapy
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • CTLA-4
  • ipilimumab
  • nivolumab
  • nsclc
  • pd-1
  • pd-l1

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC'. Together they form a unique fingerprint.

Cite this